The educational content for this programme has been designed by a steering committee of leading myeloproliferative neoplasm (MPN) specialists, in collaboration with Novartis.
Mark Drummond obtained his medical degree from the University of Glasgow, Scotland, in 1992. His haematology training was undertaken in Scotland and New Zealand.
Dr Drummond obtained a PhD in chronic leukaemia in 2004 and became a consultant in 2006. He is now based at the Beatson Cancer Centre in Glasgow, Scotland.
Dr Drummond is currently Lead Clinician for blood cancers in the west of Scotland and leads a number of UK and international clinical trials. He has authored over 40 peer-reviewed publications, including two textbooks on haematological diagnosis.
Dr Drummond’s clinical interests include the investigation and diagnosis of all blood count and haematological abnormalities.
Claire Harrison became a consultant at Guy’s Hospital, London, in 2001, where she is now also the Clinical Director of Haematology.
Professor Harrison has influenced major advances in her field, studying the description of key mutations and designing and leading global clinical trials, including the first JAK inhibitor trial in Europe. Professor Harrison is the Chief Investigator for several other national and international clinical trials.
Professor Harrison has strong international collaborations and has authored many papers in peer-reviewed journals such as the New England Journal of Medicine and Blood. She has worked with enthusiastic patients to create a patient charity, MPN Voice. Professor Harrison is internationally regarded as both an expert in her field and as a patient advocate.
Mary Frances McMullin trained in haematology and general medicine in Belfast and then at the Royal Postgraduate Medical School, Hammersmith Hospital, London.
Professor McMullin was appointed as a Senior Lecturer in 1991 and has been an active researcher and clinician in haematological malignancy in Belfast since that time. Her main research interests are in myeloproliferative disorders, acute myeloid leukaemia and chronic myeloid leukaemia. She has an active clinical practice and collaborates with scientists looking at the pathogenesis of the myeloproliferative disorders, particularly in investigations of patients with idiopathic erythrocytosis.
Professor McMullin also works on the pathogenesis and treatment of acute myeloid leukaemia and chronic myeloid leukaemia with the clinical trials unit, a number of Phase II and III trials in the areas of acute myeloid leukaemia, chronic myeloid leukaemia and myeloproliferative disorders, and is continually investigating new and improved treatments in these disorders.
Adam Mead is a Professor of haematology at the Weatherall Institute of Molecular Medicine at the University of Oxford, UK. He trained in medicine and haematology at the University of Oxford and University College London (UCL) and completed his PhD at UCL in 2007 with Professors Rosemary Gale and David Linch.
His PhD was focused on the clinical impact of different types of FLT3 mutation in acute myeloid leukaemia. Dr Mead's research is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. The overarching aim of his research group is to improve the management of myeloproliferative neoplasms, chronic myeloid leukaemia, and related conditions through better characterisation and therapeutic targeting of malignant stem and progenitor cell populations. Dr Mead’s research is closely linked with his clinical practice based at Oxford University Hospitals NHS trust, where he is Clinical Lead for MPN and CML.
Dr Mead leads the National Institute for Health Research (NIHR) MPN Clinical Studies Subgroup which oversees MPN clinical research in the UK, and he is the Principal or Chief Investigator of over 28 clinical trials in MPNs, including access to extensive sample collections linked to these clinical trials.
Mallika Sekhar is a Consultant Haematologist and Honorary Associate Professor at University College London (UCL) sub-specialising in myeloproliferative diseases and transfusion medicine across UCL Hospital and the Royal Free Hospital, London.
Her clinical and research interests are in thrombosis related to myeloproliferative diseases and transfusion in haemato-oncology. She runs a large service for MPN-related splanchnic vein thrombosis and runs the UK registry for this condition.
She has contributed to national guidelines in these areas through the British Committee for Standards in Haematology and other national bodies. She qualified from the University of Mumbai, Mumbai, India and trained further in haematology at Christian Medical College, India and in London, UK. She was appointed as a Consultant Haematologist in 1995.
The MPN Leaders Programme is organised and funded by Novartis Pharmaceuticals UK Ltd and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code. Prescribing information will be available throughout the programme for all Novartis brands mentioned. Participation in the programme will be funded by Novartis (delegate travel, accommodation and reasonable expenses will be covered in the event of a face-to-face meeting). The Steering Committee has been offered an honorarium for their involvement in this programme.
Rate this content:
HCP20-C048d October 2020.
